Key takeaways
For cystitis, three lactobacilli stand out in research: rhamnosus GR-1, reuteri RC-14, and crispatus. They support women's intimate flora, especially in preventing recurring episodes, in addition to medical follow-up.
Which Lactobacillus to choose for cystitis?
Three strains concentrate most of the scientific data on cystitis and urinary tract infections in women: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC-14, and Lactobacillus crispatus.
These lactobacilli share a common feature: they colonize the intimate flora (also called Döderlein's flora) and produce lactic acid. This acid maintains a low vaginal pH, an environment unfavorable to bacteria like E. coli, which cause the majority of cystitis cases.
Our expert solution
- 5 clinical strains, including L. crispatus, rhamnosus, and reuteri
- 20 billion CFU per day, DRcaps® gastro-resistant capsule
- Strains cultivated and analyzed in France, vegan and clean formula
The table below summarizes what research indicates for each, in the context of preventing recurrences.
| Strain | Route studied | Main documented interest |
|---|---|---|
| Lactobacillus rhamnosus GR-1 | Oral | Vaginal colonization and support of intimate flora, often associated with reuteri RC-14. |
| Lactobacillus reuteri RC-14 | Oral | Survival to intestinal transit, complementary action to GR-1 on the urogenital ecosystem. |
| Lactobacillus crispatus | Vaginal | Dominant strain of a healthy flora, studied to reduce recurrence of urinary tract infection. |
Key information: none of these strains "treat" an acute cystitis. Their documented role concerns the prevention of repeated episodes, by durably supporting the intimate flora.
Why intimate flora protects against urinary tract infections
Intimate flora and urinary tracts form a connected ecosystem. The vaginal area acts as a reservoir: when it is dominated by lactobacilli, it limits the ascent of bacteria towards the urethra and bladder.
When this balance weakens, undesirable bacteria can more easily colonize the area and trigger cystitis. Several factors weaken this flora: antibiotics, menstruation, hormonal variations, stress, or inappropriate hygiene.
This is why the strains studied for cystitis are often the same as those in the vaginal flora. Strengthening the intimate flora means strengthening this primary natural barrier in women.
Did you know?
A healthy vaginal flora mainly relies on lactobacilli, including Lactobacillus crispatus. Their presence maintains an acidic pH that hinders the development of infection-causing bacteria.
Our intimate flora probiotic: 5 strains to support your balance
We formulated our Intimate Flora Probiotic to support women's vaginal flora balance daily.
It combines 5 strains of lactobacilli, including Lactobacillus crispatus (a dominant strain of healthy flora), rhamnosus, and reuteri, for a total of 20 billion CFU per dose. The strains are cultivated and analyzed in France, without controversial additives.
It is used as a long-term treatment, particularly during sensitive periods (after antibiotic intake, during stress or hormonal fluctuations), as part of a healthy lifestyle.
Oral or vaginal route: which form to prefer?
Both routes are studied and address different rationales.
The oral route (capsule) mainly concerns the rhamnosus GR-1 and reuteri RC-14 strains. Taken by mouth, they pass through the intestine and then naturally reach the intimate sphere. This is the most practical format for a regular and discreet course of treatment.
The vaginal route (ovule, suppository) is more for crispatus, applied locally. This form directly targets the area but is more restrictive for daily use.
For preventive and comfortable long-term use, the oral route is often preferred. The choice depends on your situation: a healthcare professional can guide you.
How to choose your intimate flora probiotic
Four criteria distinguish a serious probiotic from a generic product.
- Identified strains: prefer a product that precisely names its strains (crispatus, rhamnosus, reuteri) rather than just the mention "lactobacillus".
- Sufficient dosage: expressed in CFU (colony-forming units), it indicates the quantity of living bacteria supplied.
- Protective galenic: a gastro-resistant capsule preserves the strains from stomach acidity.
- Traceability: controlled manufacturing and accessible analysis certificates are quality benchmarks.
A good intimate flora probiotic checks these four boxes and fits into a regular routine, the key to sustainably supporting flora balance.
FAQ: Your questions about Lactobacillus and cystitis
Can Lactobacillus replace antibiotic treatment for cystitis?
No. An acute cystitis requires medical advice. Lactobacilli are studied for recurrence prevention, not as treatment for an ongoing infection.
How long should I take an intimate flora probiotic?
Courses typically range from 10-20 days for occasional support to 1-3 months for a long-term effect. Regularity is key, as lactobacilli need to establish themselves gradually.
Which strain for recurrent cystitis?
The rhamnosus GR-1, reuteri RC-14, and crispatus strains are the most documented for preventing recurrences. A healthcare professional can adapt the choice to your specific case.
Can these probiotics be taken with an antibiotic?
Yes, it's common after treatment to help the flora rebalance. Space out doses by at least 2 hours to preserve the probiotics' effectiveness.
Are intimate flora probiotics suitable during pregnancy?
Most can be considered, unless contraindicated. During pregnancy or breastfeeding, always seek your doctor's advice before starting any course.
Do cranberry or D-mannose replace probiotics?
These are different and complementary approaches. Probiotics act on the flora, while other active ingredients target bacterial adhesion. Neither replaces medical follow-up.
Safety advice
Before starting any course, consult your doctor.
Scientific sources
- Abdullatif V.A. et al., "Efficacy of Probiotics as Prophylaxis for Urinary Tract Infections in Premenopausal Women: A Systematic Review and Meta-Analysis", Cureus, 2021. DOI: 10.7759/cureus.18843.
- Hemmerling A. et al., "Response to antibiotic treatment of bacterial vaginosis predicts the effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05)", medRxiv, 2023. DOI: 10.1101/2023.10.19.23297283.
- Armstrong E. et al., "Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment", The Lancet Microbe, 2022. DOI: 10.1016/S2666-5247(22)00043-X.
